GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » Effective Interest Rate on Debt %

MannKind (MannKind) Effective Interest Rate on Debt % : 7.79% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is MannKind Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. MannKind's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $21.4 Mil. MannKind's average total debt for the quarter that ended in Dec. 2023 was $275.1 Mil. Therefore, MannKind's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 7.79%.


MannKind Effective Interest Rate on Debt % Historical Data

The historical data trend for MannKind's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Effective Interest Rate on Debt % Chart

MannKind Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.74 7.74 8.03 8.58 8.97

MannKind Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.34 7.35 13.37 7.58 7.79

Competitive Comparison of MannKind's Effective Interest Rate on Debt %

For the Biotechnology subindustry, MannKind's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MannKind's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MannKind's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where MannKind's Effective Interest Rate on Debt % falls into.



MannKind Effective Interest Rate on Debt % Calculation

MannKind's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -25.161/( (288.398+272.624)/ 2 )
=-1  *  -25.161/280.511
=8.97 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=278.833 + 9.565
=288.398

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=252.624 + 20
=272.624

MannKind's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -21.42/( (277.526+272.624)/ 2 )
=-1  *  -21.42/275.075
=7.79 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=257.526 + 20
=277.526

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=252.624 + 20
=272.624

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


MannKind  (NAS:MNKD) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


MannKind Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of MannKind's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


MannKind (MannKind) Business Description

Industry
Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Executives
Michael Castagna officer: Chief Commercial Officer 25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson officer: VP & Assoc General Counsel 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder officer: Chief Financial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank officer: EVP Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: EVP Chief Operating Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh officer: EVP Technical Operations 1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo officer: Chief Commercial Officer 30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross officer: Corp VP, Chief People Officer ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio director 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur director
Sabrina Kay director 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall officer: Chief Medical Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley officer: Chief Commercial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney officer: Chief Compliance Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362